Full-Time

Senior Global Marketing Manager

Enteric & HAI

Updated on 8/26/2026

Becton Dickinson

Becton Dickinson

10,001+ employees

Global medical devices and diagnostics provider

Compensation Overview

$134.1k - $214.5k/yr

Heidelberg, Germany + 1 more

More locations: Sparks, MD, USA

Remote

Global travel to regions and customer sites is required at least 20% of the time.

Bachelor's, Master's, MBA, PharmD, PhD, MD

Category
Growth & Marketing (1)
Required Skills
Product Management
Microbiology

Get referred to Becton Dickinson

See people who can refer or advise you

Requirements
  • A Bachelor's degree is required in Life Sciences, Clinical Sciences, Marketing, or Business.
  • At least 5 years of experience in global or regional strategic marketing, product marketing, or product management within in vitro diagnostics, diagnostics, medical devices, or life sciences, with demonstrated success in commercialization, portfolio strategy, and brand leadership.
  • Proven experience working cross-functionally to develop accurate, compliant, and impactful commercial materials, including customer messaging, campaign content, sales tools, and portfolio support materials.
  • A solid understanding of regulated healthcare environments, including promotional versus non-promotional boundaries, medical review processes, and compliance standards.
  • Demonstrated ability to translate clinical evidence, guidelines, and scientific data into customer-focused marketing strategies that drive adoption and trust.
  • Experience working across global or multi-regional markets, incorporating local clinical practices, regulatory considerations, and customer needs.
  • Ability to work independently and autonomously.
  • Strategic thinking, implementation, and analytical skills, including the ability to translate insights into actionable plans and develop and implement marketing and product strategies.
  • Excellent presentation and written and oral communication skills for a wide variety of audiences.
  • Excellent interpersonal skills and the ability to develop strong relationships with cross-functional colleagues, team members, customers, and business partners.
  • Leadership presence and the ability to use organizational channels in complex and matrixed-team environments.
  • Strong organizational skills and the ability to meet tight deadlines while prioritizing multiple tasks and competing priorities.
  • Willingness and ability to travel globally to regions and customer sites at least 20% of the time.
Responsibilities
  • Define, evolve, and communicate the global marketing strategy for Enteric and HAI using market trends, customer needs, competitive dynamics, and portfolio priorities.
  • Own portfolio planning and execution for Enteric and HAI, including strategic priorities, annual marketing plans, launch readiness, and downstream commercialization support.
  • Partner with regional marketing and commercial teams to align global strategy with local market needs and enable execution and adoption across priority geographies.
  • Develop differentiated value propositions, messaging, and content that articulate the clinical, operational, and economic value of the Enteric and HAI portfolio.
  • Support global campaigns, market development initiatives, and customer engagement programs to build awareness and accelerate growth in Enteric and HAI testing markets.
  • Collaborate with Medical Affairs, Market Access, Public Health, Product Management, Research and Development, and Commercial teams to ensure aligned execution and cross-functional partnership.
  • Lead development of marketing tools and programs, including campaign assets, sales enablement materials, customer-facing content, webinars, and portfolio playbooks.
  • Provide strategic input into portfolio strategy, business cases, and annual strategic reviews using market data and customer insights to identify growth opportunities and priorities.
  • Monitor market trends, competitive activity, and customer needs across Enteric and HAI to inform strategy, positioning, and execution decisions.
  • Measure and report on business and marketing performance, including campaign impact, portfolio growth, and key performance indicators, and recommend actions to improve results.
  • Build collaborative relationships across functions and regions and act as a trusted marketing partner to drive focus, alignment, and execution.
  • Adhere to company policies, procedures, and business ethics standards to ensure compliance and integrity across marketing activities.
Desired Qualifications
  • An advanced degree, such as a Master's, PhD, PharmD, MD, or MBA.
  • Experience in infectious disease, microbiology, or diagnostics marketing, including the ability to engage credibly with customers, laboratorians, scientific stakeholders, and cross-functional partners.

BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Get referred to Becton Dickinson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
  • Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
  • Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.

What critics are saying

  • FDA classified BD’s intraosseous recall Class I on August 17, 2026.
  • The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
  • Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.

What makes Becton Dickinson unique

  • BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
  • BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
  • BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

9%

1 year growth

9%

2 year growth

9%
Yahoo Finance
Aug 18th, 2026
Wall Street analysts give Becton, Dickinson a 'moderate buy' rating despite 12% earnings decline forecast

Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".

PR Newswire
Aug 17th, 2026
BD names Gary Sorsher chief quality officer as Jeff Silvestri retires after 25 years

BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.

MedTech Dive
Aug 13th, 2026
BD fully enrolls trial of resorbable mesh for hernia prevention.

BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."

Yahoo Finance
Aug 9th, 2026
BD up 6.8% on Q3 beat, GLP-1 pen partnerships boost biologic delivery outlook

Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.

Yahoo Finance
Aug 7th, 2026
BD reports Q3 fiscal 2026 results with $5B revenue up 5.4% and adjusted EPS of $3.23

BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.